The Efficacy of Oligonol in Nonalcoholic Fatty Liver Disease: A Randomized Double-Blinded Placebo-Controlled Trial-Reference-Cited by-同舟云学术

The Efficacy of Oligonol in Nonalcoholic Fatty Liver Disease: A Randomized Double-Blinded Placebo-Controlled Trial

Published:2022-11-01 Issue:11 Volume:28 Page:904-908
ISSN:2768-3605
Container-title:Journal of Integrative and Complementary Medicine
language:en
Short-container-title:Journal of Integrative and Complementary Medicine

Author:

Chayanupatkul Maneerat¹^ORCID,Sawatdee Waleerat²,Chutaputti Anuchit³,Tangkijvanich Pisit²

Affiliation:

1. Alternative and Complementary Medicine for Gastrointestinal and Liver Diseases Research Unit, Department of Physiology, Faculty of Medicine, Chulalongkorn University, Pathumwan, Bangkok, Thailand.

2. Center of Excellence in Hepatitis and Liver Cancer, Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Pathumwan, Bangkok, Thailand.

3. Department of Medicine, Phramongkutklao Hospital, Ratchathewi, Bangkok, Thailand.

Publisher

Mary Ann Liebert Inc

Link

https://www.liebertpub.com/doi/pdf/10.1089/jicm.2021.0362

Reference23 articles.

1. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

2. Natural History of NAFLD/NASH

3. Oligonol suppresses lipid accumulation and improves insulin resistance in a palmitate-induced in HepG2 hepatocytes as a cellular steatosis model

4. Amelioration of abdominal obesity by low-molecular-weight polyphenol (Oligonol) from lychee

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quercetin intervention reduced hepatic fat deposition in patients with nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled crossover clinical trial;The American Journal of Clinical Nutrition;2024-09

2. Human diet‐derived polyphenolic compounds and hepatic diseases: From therapeutic mechanisms to clinical utilization;Phytotherapy Research;2023-10-23